What question did this study set out to answer?

February 27, 2026Open Access

A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium

Key Points

To compare safety outcomes between nivolumab plus cabozantinib and pembrolizumab plus lenvatinib in the treatment of metastatic renal cell carcinoma.
Conducted a real-world comparison
Evaluated toxicity outcomes
Analyzed treatment efficacy for mRCC
Nivolumab plus cabozantinib and pembrolizumab plus lenvatinib showed similar effectiveness in treating mRCC.
Pembrolizumab plus lenvatinib had a higher incidence of severe treatment-related adverse events.

Abstract

Nivo + Cabo and Pem + Len demonstrated similar oncologic efficacy as first-line treatments for mRCC. However, Pem + Len was associated with more severe TrAEs. Careful toxicity management and shared decision-making are essential when selecting ICI-based combinations.

Bookmark

View Full Paper

Cite This Study

Yanagisawa et al. (Wed,) studied this question.

synapsesocial.com/papers/69a134fbed1d949a99abe73c https://doi.org/https://doi.org/10.1007/s00262-025-04288-6

Bookmark

View Full Paper